Literature DB >> 16985973

Complementary medicine, chemoprevention, and staging of prostate cancer.

E David Crawford.   

Abstract

The 13th International Prostate Cancer Update was held in Vail, Colorado, in February 2003. This article provides an overview of the high points in the areas of complementary medicine, chemoprevention, and staging that were discussed at this meeting. M. Scott Lucia, MD, addressed the use of various hormonal agents, antiproliferative or differentiating agents, antiinflammatory agents, and antioxidants in patients with prostate cancer. Wael A. Sakr, MD, provided an overview of prognostic markers for this disease. Arturo Mendoza-Valdes, MD, explored the potential role of exercise for patients with prostate cancer, and Bruce Sodee, MD, described some exciting new developments in prostate imaging. E. David Crawford, MD, discussed the ongoing Prostate Cancer Prevention Trial.

Entities:  

Year:  2003        PMID: 16985973      PMCID: PMC1502373     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  18 in total

Review 1.  Prostate-specific membrane antigen: present and future applications.

Authors:  S S Chang; P B Gaudin; V E Reuter; W D Heston
Journal:  Urology       Date:  2000-05       Impact factor: 2.649

2.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

Review 3.  Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.

Authors:  U F Habenicht; M F el Etreby
Journal:  J Androl       Date:  1991 Nov-Dec

Review 4.  Physical activity and cancer prevention: from observational to intervention research.

Authors:  C M Friedenreich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-04       Impact factor: 4.254

5.  Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP).

Authors:  R Mentor-Marcel; C A Lamartiniere; I E Eltoum; N M Greenberg; A Elgavish
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

6.  Prostate cancer prevention strategies using antiproliferative or differentiating agents.

Authors:  J Walczak; H Wood; G Wilding; T Williams; C W Bishop; M Carducci
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

7.  Evaluation of biomarker modulation by fenretinide in prostate cancer patients.

Authors:  D Urban; R Myers; U Manne; H Weiss; J Mohler; D Perkins; M Markiewicz; R Lieberman; G Kelloff; M Marshall; W Grizzle
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

8.  Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice.

Authors:  J R Zhou; E T Gugger; T Tanaka; Y Guo; G L Blackburn; S K Clinton
Journal:  J Nutr       Date:  1999-09       Impact factor: 4.798

9.  Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate.

Authors:  M S Lucia; M A Anzano; M V Slayter; M R Anver; D M Green; M W Shrader; D L Logsdon; C L Driver; C C Brown; C W Peer
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

10.  Cancer statistics, 2003.

Authors:  Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2003 Jan-Feb       Impact factor: 508.702

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.